Monad Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Monad Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, grow…

2002-08-20 New Delhi, Delhi Active Unlisted Active Non-Compliant
Share
MP Monad Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Monad Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
81/100
Trust Score
Low Risk

Monad Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 81/100. Monad Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2002, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Monad Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
81/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
80/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
60/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 2 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Profitable - internal accruals available.

Charges position: 1 open (17.50 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Others1 48.0 cr
Compliance Score: 80/100 Low Risk
  • Company status is Active as per MCA.
  • Marked ACTIVE non-compliant (INC-22A).
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 55/100
NameDIN / PANDesignationAppointedTenureDIN status
AMIT JOSHI 01234567 Director 01/04/2018 6 yrs Approved
VIKAS BHARTI 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • AMIT JOSHI has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2017 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 60 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +1.42 over 1 year(s).
Operating for 23+ years.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence83/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment64/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 17.50 Lakh already registered.
  • Compliance record supports lending.
Investor view74/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 8 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
01 Jan 2020
Director ceased
ROHINI BHARTI
26 Jul 2007
Charge created
Others - 17.50 Lakh
27 Feb 2006
Director ceased
ANAND SAXENA
20 Aug 2002
Incorporated
Registered with Roc Delhi I
Director appointed
AMIT JOSHI (Director)
Director appointed
VIKAS BHARTI (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 1 financial year(s).
Net profit margin moved from 24% to 0.86.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2017 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Herb Health Fitness Private Limited U92400MH2010PTC201963 Mumbai, Maharashtra, India
Khushi Surgical And Orthopedic Private Limited U85110GJ2013PTC077517 Ahmedabad, Gujarat, India
Bose Diagnostic Centre Private Limited U00300BR1998PTC008669 Rohtas, Bihar, India
Shri Raghuwar Shayam Hospital And Research Centre Private Ltd U74899DL1989PTC034831 New Delhi, Delhi, India
Dr. Anita'S Diagnostic Private Limited U85110UP1998PTC024012 Uttar Pradesh, Uttar Pradesh, India
A.M.V. Pharmacy (India) Private Limited U24233UR2006PTC031504 Narender Nagar, Uttarakhand, India
Sumeru Knowledge Foundation U85100KA2010NPL055630 Bangalore, Karnataka, India
Dawn Healthcare India Private Limited U74120MH2012PTC234752 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Monad Pharmaceuticals Private Limited before audits and certifications: compliance score 80/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Monad Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 60/100, margin trends, ownership structure and peer set for Monad Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 81/100, distress signals and MSME payment-delay disclosures - know whether Monad Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Monad Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Monad Pharmaceuticals Private Limited an active company?

Monad Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 80/100 (Low Risk).

Is Monad Pharmaceuticals Private Limited financially healthy?

Monad Pharmaceuticals Private Limited has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.

Should I do business with Monad Pharmaceuticals Private Limited?

Its overall Trust Score is 81/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Monad Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Monad Pharmaceuticals Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Monad Pharmaceuticals Private Limited up to date with its ROC filings?

Marked ACTIVE non-compliant (INC-22A). Overall compliance score: 80/100 (Low Risk).

Is it risky to lend to Monad Pharmaceuticals Private Limited?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.